Investigational 2 mg Dose of Ozempic® (semaglutide) Injection Demonstrates Superior Reductions in Blood Sugar vs Ozempic® 1 mg in Adults With Type 2 Diabetes in a Phase 3 Trial

PLAINSBORO, N.J., June 26, 2021 /PRNewswire/ -- Novo Nordisk today presented data showing that an investigational 2 mg dose of Ozempic® (semaglutide) injection provided statistically significant and superior reductions in blood sugar (A1C) compared with Ozempic® 1 mg.1 These data were the...

from PR Newswire: https://ift.tt/35TXgN5